Please login to the form below

Not currently logged in
Email:
Password:

FDA declines approval for Eisai's Aricept

Eisai has received a complete response letter from the US Food and Drug Administration declining approval for the transdermal patch formulation of Eisai's Alzheimer's treatment Aricept

Eisai has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) declining approval for the transdermal patch formulation of Eisai's Alzheimer's treatment Aricept (donepezil hydrochloride).

The FDA has requested more information regarding the formulation and usage of the form of treatment.

Eisai has said it will collaborate with its US partner, Teikoku Pharma, and work with FDA to assess the complete response letter and determine next steps.

Teikoku developed the transdermal patch formulation of Aricept based on licence agreements with Eisai.

In June 2010, Teikoku submitted a new drug application to the FDA seeking approval to use the specific formulation of Aricept in the treatment of mild, moderate and severe stages of Alzheimer's disease.

26th April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...

Infographics